The ethics of incentives in rare disease research

Striking the right balance between ethical incentives, transparency and trust in rare disease patient recruitment.

Rare disease research is, by definition, complex. Small patient populations, high unmet need and often significant treatment burdens mean that every insight carries weight. Recruiting participants is rarely straightforward, and incentives are frequently part of the conversation.

But in rare disease research, incentives are not simply operational tools. They are ethical considerations.

When a patient population is small and often navigating serious or life-altering conditions, financial or material incentives must be handled with care. The line between fair compensation and undue influence can become blurred if not approached thoughtfully. Participants may be managing ongoing medical costs, reduced working capacity or significant caregiving responsibilities. In that context, the value of an incentive can feel amplified.

This is why sensitivity and transparency are non-negotiable. Incentives should recognise time, effort and expertise, not create pressure. Patients participating in rare disease research are not passive subjects; they are experts in their own lived experience. Compensation should reflect the value of that contribution while ensuring that participation remains genuinely voluntary and informed.

Transparency plays a critical role here. Clear communication about what participation involves, how long it will take, what will be discussed and how data will be used allows individuals to make decisions with confidence. The incentive should be presented as a gesture of appreciation, not the primary reason to take part.

Striking the right balance requires nuance. Too low, and incentives risk undervaluing participants’ time and lived expertise. Too high, and there is potential concern around coercion, particularly in vulnerable populations. Ethical review processes, compliance with industry guidance and alignment with frameworks such as those set out by organisations like the BHBIA and MRS help ensure that incentives are proportionate and appropriate.

However, compliance alone is not enough.

Researchers must also consider tone, delivery and context. How is the invitation phrased? Is participation framed respectfully? Are pause points built into the process? Are participants reminded that they can withdraw at any time without consequence? In rare disease research especially, the emotional dimension should not be overlooked.

There is also a practical consideration. Trust is central in rare disease communities. Word travels quickly within patient networks. If incentives feel inappropriate or transactional, reputational damage can follow. Conversely, when participants feel valued, respected and properly supported, engagement becomes stronger and more sustainable.

At Acumen Health, we approach incentives as part of a broader participant-first philosophy. That means careful calibration, open communication and a commitment to ensuring that recognition never tips into pressure. In rare disease research, the objective is insight grounded in lived reality. That insight is only meaningful if it is gathered ethically.